To further improve efficacy and minimize adverse effects, EBV specific CAR-T and TCR engineered T cell therapies targeting EBV latent protein LMP1, LMP2 and/or EBNA1 have been developed, with the goal of specific killing of EBV+ cancer cells highly efficiently. Here, PDLIM7 is linked to cancer.